Pulse Biosciences Announces Treatment Of Patients In First-In-Human Study With Its Nano-PFA Cardiac Surgery System
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences has announced the treatment of the first two patients in a first-in-human feasibility study using its Nano-PFA Cardiac Surgery System for atrial fibrillation. The system is also enrolled in the FDA's Total Product Life Cycle Advisory Program.
August 08, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences has treated the first two patients in a feasibility study using its Nano-PFA Cardiac Surgery System for atrial fibrillation. The system is also part of the FDA's TPLC Advisory Program.
The successful treatment of the first patients in a feasibility study is a significant milestone for Pulse Biosciences. Additionally, the system's enrollment in the FDA's TPLC Advisory Program suggests regulatory support, which could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100